Rosiglitazone ( DrugBank: Rosiglitazone )

5 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	3
75	Cushing disease	1
97	Ulcerative colitis	2
222	Primary nephrotic syndrome	1
265	Lipodystrophy	2

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-000482-35-LT (EUCTR)	08/11/2005	26/09/2005	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflamm ...	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflamm ...	Rheumatoid Arthritis	Product Name: RosiglitazoneExtended Release Tablets Product Code: BRL-049653 INN or Proposed INN: Rosi ...	GlaxoSmithKline Research & Development Ltd.	NULL	Not Recruiting			Female: yes Male: yes	96		United Kingdom;Lithuania
2	NCT00379600 (ClinicalTrials.gov)	November 2004	21/9/2006	The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflamm ...	Arthritis, Rheumatoid	Drug: rosiglitazone XR	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	96	Phase 2	Lithuania;United Kingdom
3	EUCTR2004-000482-35-GB (EUCTR)	11/10/2004	08/02/2005	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflamm ...	A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflamm ...	Rheumatoid Arthritis	Product Name: RosiglitazoneExtended Release Tablets Product Code: BRL-049653 INN or Proposed INN: Rosi ...	GlaxoSmithKline Research & Development Ltd.	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Lithuania;United Kingdom

First Previous1Next Last

75. Cushing disease

Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00612066 (ClinicalTrials.gov)	April 2007	8/2/2008	Rosiglitazonein Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disea ...	An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglit ...	Cushing's Disease	Drug: rosiglitazone maleate	Jonsson Comprehensive Cancer Center	National Institutes of Health (NIH)	Terminated	18 Years	65 Years	All	2	Phase 2	United States

First Previous1Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00309660 (ClinicalTrials.gov)	November 2005	30/3/2006	Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis		Ulcerative Colitis	Drug: Rosiglitazone	Herlev Hospital	NULL	Recruiting	18 Years	80 Years	Both	20	Phase 1/Phase 2	Denmark
2	NCT00065065 (ClinicalTrials.gov)	September 2002	16/7/2003	A Trial of Rosiglitazone for Ulcerative Colitis	A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis	Ulcerative Colitis;Inflammatory Bowel Disease	Drug: Rosiglitazone;Drug: Placebo	James Lewis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);GlaxoSmithKline	Completed	18 Years	N/A	All	105	Phase 2	United States

First Previous1Next Last

222. Primary nephrotic syndrome

Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00193648 (ClinicalTrials.gov)	July 2005	10/9/2005	Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)	Novel Therapies for Resistant FSGS	Focal Glomerulosclerosis	Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira)	North Shore Long Island Jewish Health System	University of North Carolina;The Cleveland Clinic	Completed	2 Years	40 Years	Both	21	Phase 1	United States

First Previous1Next Last

265. Lipodystrophy

Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00130286 (ClinicalTrials.gov)	March 2005	12/8/2005	Growth Hormone and/or Rosiglitazonefor HIV-Associated Increased Abdominal Fat and Insulin Resistance ...	Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human G ...	HIV-Associated Lipodystrophy Syndrome;Insulin Resistance;HIV Infections;Metabolic Syndrome X;Body We ...	Drug: Rosiglitazone;Drug: Recombinant human growth hormone + rosiglitazone	Weill Medical College of Cornell University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	65 Years	All	77	Phase 1/Phase 2	United States
2	NCT00015691 (ClinicalTrials.gov)	April 2001	1/5/2001	Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat ...	A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Com ...	HIV Infections;Lipodystrophy;Hyperinsulinemia	Drug: Metformin hydrochloride;Drug: Rosiglitazone maleate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	65 Years	Both	105	N/A	United States

First Previous1Next Last